Brett Leav

7.6k citations

36 papers · 2.0k indexed · 2 hit papers · h-index 19

Co-authors: Deborah C. Molrine Barbra M. Blair Donna M. Ambrosino Roger Baxter Mark D. Leney Israel Lowy Dale N. Gerding Honorine Ward
Topics: Influenza Virus Research Studies (11 papers)SARS-CoV-2 and COVID-19 Research (9 papers)Respiratory viral infections research (8 papers)
Cited by: Infectious Diseases Parasitology Epidemiology
Journals: New England Journal of Medicine Nature Medicine Gastroenterology
Partner nations: United States Finland Philippines

In The Last Decade

Brett Leav

36 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment with Monoclonal Antibodies against Clostridium difficile Toxins

2010 557 citations Israel Lowy, Deborah C. Molrine et al. New England Journal of Medicine profile →
The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials

2023 97 citations Brandon Essink, Laurence Chu et al. The Lancet Infectious Diseases profile →

Peers

Countries citing papers authored by Brett Leav

Since Specialization

Citations

This map shows the geographic impact of Brett Leav's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brett Leav with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brett Leav more than expected).

Fields of papers citing papers by Brett Leav

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brett Leav. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brett Leav. The network helps show where Brett Leav may publish in the future.

Co-authorship network of co-authors of Brett Leav

This figure shows the co-authorship network connecting the top 25 collaborators of Brett Leav. A scholar is included among the top collaborators of Brett Leav based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brett Leav. Brett Leav is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients 2023 ·Cancer Communications ·Anna R. Giuliano,Barbara J. Kuter,Shari Pilon‐Thomas,Junmin Whiting,Qianxing Mo,Brett Leav,Bradley Sirak,Christopher Cubitt,(unknown),(unknown),(unknown),Somedeb Ball,(unknown),Akriti Jain,Patrick Hwu,Jeffrey E. Lancet	6
2	No Immunological Interference or Safety Concerns When Adjuvanted Recombinant Zoster Vaccine Is Coadministered With a Coronavirus Disease 2019 mRNA-1273 Booster Vaccine in Adults Aged 50 Years and Older: A Randomized Trial 2023 ·Clinical Infectious Diseases ·(unknown),(unknown),(unknown),Brett Leav,Jacqueline M. Miller,(unknown),(unknown),Thomas Breuer,Agnes Mwakingwe-Omari	6
3	Stochastic interventional approach to assessing immune correlates of protection: Application to the COVE messenger RNA-1273 vaccine trial 2023 ·International Journal of Infectious Diseases ·Nima S. Hejazi,Xiaoying Shen,Lindsay N. Carpp,David Benkeser,Dean Follmann,Holly Janes,Lindsey R. Baden,Hana M. El Sahly,Weiping Deng,Haiyu Zhou,Brett Leav,David C. Montefiori,Peter B. Gilbert	2
4	The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trialsbreakdown → 2023 ·The Lancet Infectious Diseases ·Brandon Essink,Laurence Chu,(unknown),Elizabeth Barranco,(unknown),Hamilton Bennett,(unknown),Rolando Pajón,Yamuna Devi Paila,(unknown),Steven Wang,(unknown),(unknown),Brett Leav	97
5	Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial 2022 ·Nature Medicine ·Laurence Chu,Keith Vrbicky,David C. Montefiori,Wenmei Huang,Biliana Nestorova,Ying Chang,Andrea Carfı́,Darin K. Edwards,Judy Oestreicher,Holly Legault,(unknown),Bethany Girard,Rolando Pajón,Jacqueline M. Miller,Rituparna Das,Brett Leav,Roderick McPhee	56
6	A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273) 2022 ·Vaccine ·Brett Leav,Walter L. Straus,P. White,(unknown),(unknown),(unknown),(unknown),Emily Smith,Marc Gurwith,Robert T. Chen	5
7	Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial 2022 ·Nature Medicine ·Spyros Chalkias,Frank Eder,Brandon Essink,(unknown),Biliana Nestorova,Jing Feng,Xing Chen,Ying Chang,Haiyu Zhou,David C. Montefiori,Darin K. Edwards,Bethany Girard,Rolando Pajón,(unknown),Brett Leav,Stephen R. Walsh,Lindsey R. Baden,Jacqueline M. Miller,Rituparna Das	70
8	Prevention of influenza during mismatched seasons in older adults with an MF59-adjuvanted quadrivalent influenza vaccine: a randomised, controlled, multicentre, phase 3 efficacy study 2021 ·The Lancet Infectious Diseases ·Jiřı́ Beran,Humberto Reynales,Airi Põder,Charles Yu,Punnee Pitisuttithum,(unknown),Wim Vermeulen,Carole Verhoeven,Brett Leav,Bin Zhang,(unknown),(unknown),Jonathan M. Edelman,Igor Smolenov	33
9	A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine 2021 ·Vaccine ·Laurence Chu,Roderick McPhee,Wenmei Huang,Hamilton Bennett,Rolando Pajón,Biliana Nestorova,Brett Leav	146
10	Comparability of Titers of Antibodies against Seasonal Influenza Virus Strains as Determined by Hemagglutination Inhibition and Microneutralization Assays 2020 ·Journal of Clinical Microbiology ·Marten Heeringa,Brett Leav,Igor Smolenov,Giuseppe Palladino,Leah Isakov,(unknown)	15
11	A phase 1, randomized, observer blind, antigen and adjuvant dosage finding clinical trial to evaluate the safety and immunogenicity of an adjuvanted, trivalent subunit influenza vaccine in adults ≥ 65 years of age 2019 ·Vaccine ·Gillis R. Otten,(unknown),Max Ciarlet,Brett Leav	3
12	Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults ≥65 years of age: Meta-analysis of cumulative clinical experience 2019 ·International Journal of Infectious Diseases ·Uwe Nicolay,Esther Heijnen,Pantaleo Nacci,P. Patriarca,Brett Leav	35
13	Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children and adults 65 years of age and older 2019 ·International Journal of Infectious Diseases ·Kelly Lindert,Brett Leav,Esther Heijnen,Julia Barrett,Uwe Nicolay	10
14	2556. Retrospective Evaluation of Mismatch From Egg-Based Isolation of Influenza Strains Compared With Cell-Based Isolation and the Possible Implications for Vaccine Effectiveness 2018 ·Open Forum Infectious Diseases ·(unknown),(unknown),Brett Leav,Pirada Suphaphiphat,Ike Iheanacho,Kristin Kistler	18
15	Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial 2018 ·The Lancet Respiratory Medicine ·Timo Vesikari,Judith L. Kirstein,(unknown),Brett Leav,(unknown),Leah Isakov,(unknown),Janine Oberyé,Esther Heijnen	47
16	Human Monoclonal Antibody HCV1 Effectively Prevents and Treats HCV Infection in Chimpanzees 2012 ·PLoS Pathogens ·Trevor J. Morin,Teresa J. Broering,Brett Leav,Barbra M. Blair,Kirk J. Rowley,(unknown),Yang Wang,Peter Cheslock,(unknown),David B. Olsen,(unknown),Gyöngyi Szabó,Robert W. Finberg,Robert H. Purcell,Robert E. Lanford,Donna M. Ambrosino,Deborah C. Molrine,Gregory J. Babcock	133
17	Treatment with Monoclonal Antibodies against Clostridium difficile Toxinsbreakdown → 2010 ·New England Journal of Medicine ·Israel Lowy,Deborah C. Molrine,Brett Leav,Barbra M. Blair,Roger Baxter,Dale N. Gerding,Geoffrey Nichol,William D. Thomas,Mark D. Leney,Susan Sloan,Catherine A. Hay,Donna M. Ambrosino	557
18	Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI) 2009 ·Vaccine ·Brett Leav,Barbra M. Blair,Mark D. Leney,(unknown),(unknown),Israel Lowy,Dale N. Gerding,Ciarán P. Kelly,(unknown),Roger Baxter,Donna M. Ambrosino,Deborah C. Molrine	193
19	Early alterations in ras protooncogene mRNA expression in testosterone and estradiol-17 beta induced prostatic dysplasia of noble rats. 1993 ·PubMed ·(unknown),Brett Leav,Irwin Leav,F. B. Merk,Hubert J. Wolfe,S.-M. Ho	29
20	The detection of Epstein-Barr virus in hairy cell leukemia cells by in situ hybridization. 1990 ·PubMed ·(unknown),(unknown),Richard S. Neiman,Anthony J. Janckila,L T Yam,(unknown),Brett Leav,(unknown),Daniel S. Schultz,Hubert J. Wolfe	15

About Brett Leav

Brett Leav is a scholar working on Infectious Diseases, Parasitology and Epidemiology, having authored 36 papers that have together received 2.0k indexed citations. Recurring topics across this work include Influenza Virus Research Studies (11 papers), SARS-CoV-2 and COVID-19 Research (9 papers) and Respiratory viral infections research (8 papers). The work is most often cited by research in Infectious Diseases (1.3k citations), Parasitology (296 citations) and Epidemiology (880 citations). Brett Leav has collaborated with scholars based in United States, Finland and Philippines. Frequent co-authors include Deborah C. Molrine, Barbra M. Blair, Donna M. Ambrosino, Roger Baxter, Mark D. Leney, Israel Lowy, Dale N. Gerding, Honorine Ward, Susan Sloan and William D. Thomas. Their work appears in journals such as New England Journal of Medicine, Nature Medicine and Gastroenterology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact